Abstract
Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug. The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse – effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research. Relevant Englishlanguage literature was identified through searches of NCI, PubMed, ASCO.org and ESMO, ECCO meetings proceedings.
Keywords: Capecitabine, esophageal cancer, gastric cancer, gastroesophageal cancer, colorectal cancer, hepatic cancer, biliary tract cancer, gallbladder cancer, pancreatic cancer
Reviews on Recent Clinical Trials
Title: The Role of Capecitabine in the Management of Tumors of the Digestive System
Volume: 4 Issue: 1
Author(s): Constantine Gennatas, Vasiliki Michalaki and Spyridon Gennatas
Affiliation:
Keywords: Capecitabine, esophageal cancer, gastric cancer, gastroesophageal cancer, colorectal cancer, hepatic cancer, biliary tract cancer, gallbladder cancer, pancreatic cancer
Abstract: Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug. The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse – effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research. Relevant Englishlanguage literature was identified through searches of NCI, PubMed, ASCO.org and ESMO, ECCO meetings proceedings.
Export Options
About this article
Cite this article as:
Gennatas Constantine, Michalaki Vasiliki and Gennatas Spyridon, The Role of Capecitabine in the Management of Tumors of the Digestive System, Reviews on Recent Clinical Trials 2009; 4 (1) . https://dx.doi.org/10.2174/157488709787047576
DOI https://dx.doi.org/10.2174/157488709787047576 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Polymorphism of miR-218-2 (rs11134527) in Cervical Cancer: A
Case-Control Study on the Bangladeshi Women
MicroRNA High Throughput Screening of Normal and Neoplastic Tissue Samples
Combinatorial Chemistry & High Throughput Screening The Targets of Curcumin
Current Drug Targets Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine The Impact of DIDS-Induced Inhibition of Voltage-Dependent Anion Channels (VDAC) on Cellular Response of Lymphoblastoid Cells to Ionizing Radiation
Medicinal Chemistry B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin
Current Medicinal Chemistry Cancer Chemoprevention Drug Targets
Current Drug Targets Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Biomarker Assessment in Nutritional Modulation of Oxidative Stress-Induced Cancer Development by Lipid-Related Bioactive Molecules
Recent Patents on Anti-Cancer Drug Discovery Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design Costimulation, Coinhibition and Cancer
Current Cancer Drug Targets Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Dendritic Cells in Colorectal Cancer and a Potential for their Use in Therapeutic Approaches
Current Pharmaceutical Design Cellomics as Integrative Omics for Cancer
Current Proteomics Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Management of Postoperative Nausea and Vomiting in Women Undergoing Major Gynecological Surgery: A Review and Update
Current Drug Therapy Potential for Predicting Toxicity and Response of Fluoropyrimidines in Patients
Current Drug Targets Hypersensitivity to Aurora Kinase Inhibitors in Cells Resistant against Platinum- Containing Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry